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Promotes Bacterial Attachment to Glycosaminoglycans
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Borrelia burgdorferi, the agent of Lyme disease, causes a multisystemic illness that can affect the skin,
heart, joints, and nervous system and is capable of attachment to diverse cell types. Among the host
components recognized by this spirochete are fibronectin and glycosaminoglycans (GAGs). Three surface-
localized GAG-binding bacterial ligands, Bgp, DbpA, and DbpB, have been previously identified, but
recent studies suggested that at least one additional GAG-binding ligand is expressed on the spirochetal
surface when the spirochete is adapted to the mammalian host environment. BBK32 is a surface lipopro-
tein that is produced during infection and that has been shown to bind to fibronectin. In this study, we
show that, when BBK32 was produced from a shuttle vector in an otherwise nonadherent high-passage B.
burgdorferi strain, the protein localized on the bacterial surface and conferred attachment to fibronectin
and to mammalian cell monolayers. In addition, the high-passage strain producing BBK32 bound to
purified preparations of the GAGs dermatan sulfate and heparin, as well as to these GAGs on the surfaces
of cultured mammalian cells. Recombinant BBK32 recognized purified heparin, indicating that the bacterial
attachment to GAGs was due to direct binding by BBK32. This GAG-binding activity of BBK32 is apparently
independent of fibronectin recognition, because exogenous heparin had no effect on BBK32-mediated bacterial
binding to fibronectin.
Lyme disease, the most prevalent vector-borne illness in the
United States, results from infection by the spirochete Borrelia
burgdorferi. Following the bite from an infected Ixodes tick,
these spirochetes establish a local infection in the skin, often
giving rise to a characteristic rash termed erythema migrans.
Some B. burgdorferi strains are capable of dissemination to
multiple secondary sites, such as distant skin sites, brain, heart,
or joints, and the presence of spirochetes in these tissues re-
sults in diverse clinical manifestations, including arthritis, car-
ditis, neuroborreliosis, and acrodermatitis (44, 52, 53; for a
review, see reference 46).
For many bacterial pathogens, attachment to host tissues is
believed to be a critical step during colonization and is typically
mediated by adhesins, i.e., surface proteins that promote bac-
terial attachment to host cells (16). Consistent with its ability to
cause a multisystemic infection in mammals, B. burgdorferi
attaches to a variety of cell types in vitro, including lympho-
cytes, platelets, epithelial cells, endothelial cells, and neuroglia
(9, 11, 19, 20, 49, 50). Among the host cell components recog-
nized are integrins (7, 8), fibronectin (21, 39, 49), and proteo-
glycans (23, 24, 29). Proteoglycans consist of a core protein
covalently linked to glycosaminoglycans (GAGs), which are
long, linear, and highly sulfated disaccharide repeats (for a
review, see reference 48). Classes of GAGs, such as heparin,
heparan sulfate, dermatan sulfate, and chondroitin-6-sulfate,
differ in structure and are often functionally distinguished by
their differential sensitivities to cleavage by specific lyases.
In addition to binding to intact proteoglycans, B. burgdorferi
is capable of attachment to GAG chains (24, 29, 30), and
culture of B. burgdorferi under “host-adapted” conditions in
dialysis membrane chambers implanted in the rat peritoneal
cavity (1) results in significantly enhanced binding to both
endothelial cells and heparin, suggesting that GAG binding
may play an important role within the mammalian host (37). In
fact, production of the GAG-binding adhesin Vsp2 by the
related relapsing fever spirochete Borrelia turicatae is associ-
ated with efficient colonization of the joint and blood of in-
fected SCID mice, while production of a related protein, Vsp1,
which does not efficiently bind GAGs, is associated with infec-
tion of the brain (5, 33, 38, 54). For B. burgdorferi, different
classes of GAGs mediate in vitro bacterial attachment to dif-
ferent types of mammalian cells, e.g., heparan sulfate largely
mediates attachment of B. burgdorferi to cultured endothelial
cells, whereas dermatan sulfate and heparan sulfate promote
spirochetal attachment to cultured glial cells (31). In addition,
the particular GAG-binding specificity varies with the partic-
ular B. burgdorferi strain, resulting in corresponding differences
in the spectrum of cell types to which each strain binds. Thus,
a B. burgdorferi strain that binds dermatan sulfate and heparan
sulfate attaches to both glial and endothelial cells, whereas an-
other strain that binds only dermatan sulfate selectively binds glial
cells (36).
A simple hypothesis to explain these results is that B. burg-
dorferi produces multiple GAG-binding adhesins and that the
repertoire of adhesins produced by a given strain is responsible
for its particular GAG binding specificity. In fact, three GAG-
binding surface proteins have been identified. Bgp (Borrelia
GAG-binding protein) is a heparin-binding hemagglutinin that
is both secreted into the media and localized on the bacterial
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surface (6, 35). Decorin binding protein A (DbpA) and DbpB
are surface lipoproteins that, in addition to binding the pro-
teoglycan decorin (22), bind to GAGs (17, 37). Bgp, DbpA,
and DbpB do not appear to entirely account for the enhanced
GAG-binding activity displayed by host-adapted bacteria (37),
suggesting that this pathogen encodes at least one additional
GAG-binding pathway.
Upon prolonged culture, B. burgdorferi commonly loses plas-
mids that are required for full infectivity in mice but not re-
quired for in vitro growth (2, 25, 27, 34, 41, 45). B. burgdorferi
strain B314 is a high-passage derivative of strain B31 that has
lost many plasmids, including the plasmid carrying dbpA and
dbpB (43), and is incapable of attaching to mammalian cells in
vitro (17). The absence of potentially redundant binding path-
ways encoded by strain B314 greatly simplifies characterization
of the cell binding activities of ectopically expressed adhesins,
and we recently showed that expression of dbpA or dbpB from
a shuttle vector (47) conferred on B. burgdorferi strain B314
distinct GAG- and mammalian cell-binding phenotypes (17).
Strain B314 also lacks lp36, which encodes BBK32, a 47-kDa
surface lipoprotein that recognizes the extracellular matrix
protein fibronectin (18, 39). In the present study, we produced
BBK32 in B314 and demonstrated that the protein promotes
spirochetal attachment to host cells not only by recognizing
fibronectin but also by recognizing GAGs.
MATERIALS AND METHODS
Bacterial strains and cell lines. All strains of B. burgdorferi were cultured in
BSK-H complete medium (Sigma Chemical Co., St. Louis, MO) at 33°C. Borrelia
transformants were cultured in BSK-H complete medium supplemented with
kanamycin (200 g/ml). The high-passage B314 B. burgdorferi strain was a gen-
erous gift from Tom Schwan (RML, Hamilton, MT). 293 human kidney epithe-
lial, HEp-2 human epithelial, C6 rat glioma, and EAhy-926 human endothelial
cells were cultured as described previously (36).
Plasmids and cloning. To generate a recombinant maltose-binding protein
(MBP)–BBK32 fusion protein that lacked the BBK32 signal sequence and lipid
moiety, codons 21 to 354 of the strain B31 BBK32 were amplified using forward
primer 5-CGGAATTCGATTTATTCATAAGATAT-3 and reverse primer
5-GCAAGCTTTAAGTACCAAACGCCATTCTT-3 (restriction sites under-
lined) and cloned into the pMal-c2 vector (Novagen, Madison, WI). The result-
ing plasmid, pMBP-BBK32, was transformed into Escherichia coli BL21 and its
sequence confirmed by DNA sequencing. To construct a shuttle vector that
promoted expression of cloned genes during in vitro culture of B. burgdorferi, the
strain B31 ospC promoter (nucleotides 184 to 9), which is active during
growth in BSK-H (43), was amplified using PCR with forward primer 5-CCC
AAGCTTTTAATTTTAGCATATTTGGCTTTG-3 and reverse primer 5-ACG
CGTCGACCCTCCTTTTTATTTATGAATTATT-3 (restriction sites under-
lined). This 175-bp amplicon was ligated into the HindIII and SalI sites of shuttle
vector pBSV2 (47) (generously provided by Patricia Rosa, RML, Hamiliton,
MT) to generate pJF21. To modify pJF21 to produce BBK32 in vitro, the entire
BBK32 gene, encoding full-length BBK32 (354 amino acids), was amplified by
PCR using forward primer 5-ACGCGTCGACATGAAAAAAGTTAAAAG
TAAATATTTGG-3 and reverse primer 5-CGCGGATCCGTACCAAACGCC
ATTCTTGTCAATGATCC-3 and was inserted into the SalI and BamHI sites
of pJF21 to generate pBBK32B31, herein referred to as “pBBK32.”
Electroporation of B. burgdorferi B314. Electrocompetent B314 spirochetes
were transformed with 30 g of plasmid DNA and cultured in BSK-H complete
medium at 37°C for 24 h as previously described (17). Aliquots of the culture
were mixed with 1.8% analytical grade agarose (Bio-Rad, Hercules, CA) and
plated onto a solidified BSK-H–agarose layer in sterilized 100- by 20-mm tissue
culture dishes (Falcon) in the presence of kanamycin (200 g/ml). Plates were
incubated at 37°C in a 5% CO2 atmosphere for 2 weeks. Colonies were selected
and cultured at 37°C in liquid BSK-H medium containing kanamycin (200 g/ml)
until mid-logarithmic phase and then stored at 80°C in BSK-H containing 20%
glycerol.
Generation of BBK32 antiserum. MBP and MBP-BBK32 were purified from
pMAL-c2 and pMBP-BBK32, respectively, using an amylose column (New
England Biolabs, Beverly, MA) according to the manufacturer’s instructions.
Five- to 6-week-old BALB/c mice were immunized with 200 g of either MBP or
MBP-BBK32 in complete Freund’s adjuvant. The animals were boosted twice
with 200 g of the same proteins in incomplete Freund’s adjuvant at 2-week
intervals, and antisera were prepared after terminal cardiac puncture.
Proteinase K treatment, SDS-PAGE, and Western blotting. To detect BBK32
protein, lysates from 1  107 bacteria were separated by 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). BBK32 and FlaB were
identified by immunoblotting using a polyclonal antibody against MBP-BBK32
(diluted 1:10,000) or monoclonal antibody CB1 (a gift from J. Benach, Stony
Brook University, Stony Brook, NY) against FlaB (diluted 1:200), respectively.
Surface localization of BBK32 was determined as previously described (39).
Briefly, 1  107 bacteria were centrifuged and pellets were washed twice with
phosphate-buffered saline (PBS). After the final wash, pellets were gently lifted
with 5 mM MgCl2 in PBS supplemented with 4 mg/ml proteinase K (Roche,
Indianapolis, IN) and incubated at room temperature for 30 min. To inactivate
proteinase K, 150 g phenylmethylsulfonyl fluoride was added to each pellet.
Pellets were washed twice with 5 mM MgCl2 in PBS, lysed, and separated by 10%
SDS-PAGE. Proteins were identified by immunoblotting as described above.
Radiolabeling B. burgdorferi. Radiolabeled spirochetes were prepared by cul-
turing at 33°C in BSK-H medium supplemented with 60 Ci of [35S]methionine
and [35S]cysteine per ml. When cultures achieved mid-log-phase density (about
5  107 bacteria per ml), spirochetes were centrifuged at 10,000  g, washed
three times with 0.2% bovine serum albumin (BSA) in PBS, and stored as
aliquots at 80°C in BSK-H containing 20% glycerol.
Attachment of radiolabeled bacteria to purified GAGs and fibronectin. Prior
to each assay, wells from Nunc 96-well break-apart microtiter plates were coated
with either 1 mg/ml purified human fibronectin or 5 mg/ml dermatan sulfate,
heparin, or chondroitin-6-sulfate in PBS at 4°C overnight. Wells were washed
three times with 0.5% Tween in PBS. Frozen aliquots of radiolabeled spirochetes
were thawed and resuspended at 1  108 cells/ml in BSK-H and were incubated
at room temperature for 2 h. Radiolabeled spirochetes were then diluted 1:3 with
10 mM glucose, 50 mM NaCl, and 10 mM HEPES, at pH 7.0, and added in
quadruplicate wells at 1  106 spirochetes/well. To enhance substrate-spirochete
contact, plates were centrifuged at 190  g for 5 min and then rocked at room
temperature for 1 h. Unbound spirochetes were removed by washing wells four
times with 0.2% BSA in PBS. Plates were then air dried, and the percentage of
bound bacteria in each well was determined by liquid scintillation.
Attachment of radiolabeled bacteria to mammalian cells. One day before each
assay, mammalian cells were lifted with 0.05% trypsin and 0.53 mM EDTA
(Gibco BRL) and plated in Nunc 96-well break-apart microtiter plates previously
UV sterilized and coated with 2 g/ml MBP-Inv497, an MBP fused to the invasin
protein from Yersinia pseudotuberculosis (28). Just before the addition of radio-
labeled spirochetes, cell monolayers were washed twice with PBS.
Inhibition of binding with exogenous GAGs. Radiolabeled spirochetes were
prepared as described above and were incubated for 30 min at room temperature
in BSK-H supplemented with 2 mg/ml GAGs. Following incubation, spirochetes
were diluted 1:3 with 10 mM glucose, 50 mM NaCl, and 10 mM HEPES at pH
7.0 before addition to wells containing cell monolayers or coated with fibronectin
or GAG.
Enzymatic removal of specific classes of GAGs. Monolayers were incubated
for 2 h with 0.5 U/ml heparinase I, heparitinase, or chondroitinase ABC (Sigma)
at 37°C in RPMI 1640 supplemented with 1% BSA, 102 trypsin inhibitory
units/ml aprotinin, and 165 g/ml phenylmethylsulfonyl fluoride. After the
monolayers were washed twice with PBS, radiolabeled spirochetes were added to
treated monolayers as described above.
RESULTS
Expression of BBK32 in strain B314 results in localization
of the lipoprotein on the spirochetal surface and confers spi-
rochetal binding to fibronectin and cultured mammalian cells.
Some strains of B. burgdorferi do not express BBK32 during
in vitro culture (14, 39). To ensure high-level expression of
BBK32 in our standard nonadherent B. burgdorferi strain B314,
we first modified the shuttle vector pBSV2 (47) to carry the
promoter for ospC, which is expressed by this strain during in
vitro culture (43) (see Materials and Methods). The BBK32
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gene from low-passage B. burgdorferi strain B31 was inserted
into the modified shuttle vector pJF21 to generate pBBK32.
Strain B314, which as mentioned above lacks the plasmid en-
coding BBK32 (18), was transformed with pBBK32, and im-
munoblotting of bacterial lysates with antiserum raised against
an MBP-BBK32 fusion, or, as a control, against MBP, revealed
that B314/pBBK32 produced abundant BBK32, whereas B314
harboring the control vector pJF21 produced none (Fig. 1A).
In fact, B314/pBBK32 produced BBK32 at higher levels than
did the low-passage strain B31. Far-Western blotting of lysates
of B314/pBBK32 with purified fibronectin revealed that the
BBK32 produced by this strain was competent for binding
fibronectin (Fig. 1A, bottom). BBK32 produced by B314/
pBBK32, but not control periplasmic FlaB protein, was de-
graded by exposure of spirochetes to proteinase K, demon-
strating that the BBK32 was produced predominantly on the
surface of the transformant (Fig. 1B).
In order to determine whether production of BBK32 is suf-
ficient to promote spirochete attachment to fibronectin, strain
B314 harboring either the shuttle vector pJF21 or pBBK32 was
tested for the ability to bind to mock-coated wells or wells
coated with fibronectin. Transformants expressing BBK32, but
not control transformants, specifically attached to immobilized
fibronectin (Fig. 2). In fact, B314/pBBK32 bound to fibronectin
significantly better than did strain B31, consistent with its higher
level of BBK32 production.
Cultured mammalian cells commonly produce fibronectin
(10), so BBK32 was tested for the ability to mediate attach-
ment of strain B314 to different types of cultured mammalian
cells. B314/pBBK32, but not B314 harboring the vector con-
trol, bound efficiently to 293 kidney epithelial cells, EA-Hy926
endothelial cells, and C6 glial cells (Fig. 3). For each cell line,
the level of attachment of B314/pBBK32 exceeded that of
strain B31, suggesting that, in these assays, the overproduction
of BBK32 was more than sufficient to compensate for the
absence of binding pathways mediated by DbpA or DbpB,
which are not produced by B314/pBBK32 (17).
BBK32 recognizes glycosaminoglycans on the surface of mam-
malian cells and promotes spirochete attachment to purified
GAGs. It has been reported that HEp-2 epithelial cells do not
produce fibronectin (12), and we confirmed that these cells,
when cultured under our laboratory conditions, did not pro-
duce detectable fibronectin (Table 1). Unexpectedly, B314/
pBBK32 bound to HEp-2 cells virtually as efficiently as it
bound to 293, EA-Hy926, and C6 cells, which produce easily
detectable amounts of fibronectin (Fig. 3, Table 1), suggesting
that fibronectin is not the sole receptor for BBK32 produced by
mammalian cells. Bacteria that have been grown in dialysis
membrane chambers in the rat peritoneum display consider-
ably higher levels of GAG binding than do bacteria grown in
FIG. 1. BBK32 is expressed on the surface of a nonadherent B.
burgdorferi strain. (A) Lysates of low-passage B. burgdorferi B31, B.
burgdorferi B314 harboring pBBK32 (“B314/pBBK32”), or the control
vector pJF21 (“B314/vector”) were separated by 10% SDS-PAGE and
immunoblotted with the indicated antibodies (, anti) or far-Western
blotted with fibronectin (“Fn/Fn”). (B) Intact spirochetes were briefly
digested with proteinase K, and lysates prepared from these spiro-
chetes were separated by 10% SDS-PAGE and immunoblotted with
the indicated antibodies.
FIG. 2. Expression of BBK32 in a nonadherent B. burgdorferi strain
promotes efficient attachment to fibronectin. Radiolabeled strains B31,
B314/pJF21 (“B314/vector”), and B314/pBBK32 were added to mock-
coated wells or wells coated with fibronectin. The percentage of cells
stably bound was determined by liquid scintillation counting. Each bar
represents the mean of four independent determinations  the stan-
dard deviation. Asterisk indicates that binding of B314/pBBK32 to
fibronectin was significantly greater (P  0.05) than binding of B314/
vector.
FIG. 3. BBK32 promotes spirochetal attachment to cultured epi-
thelial cells independently of fibronectin. Radiolabeled strains B31,
B314/pJF21 (“vector”), and B314/pBBK32 were added to wells con-
taining monolayers of 293 epithelial, EAhy-926 endothelial, C6 glial, or
HEp-2 epithelial cells (Fn deficient), and the percentage of cells stably
bound was determined. Each bar represents the mean of four inde-
pendent determinations  the standard deviation. Asterisks indicate
that binding of B314/pBBK32 to the denoted cell lines was significantly
greater (P  0.05) than binding by B314/vector.
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vitro, and this “host-induced” GAG binding activity could not
be entirely accounted for by DbpA, DbpB, or Bgp, the previ-
ously identified GAG binding surface proteins of B. burgdorferi
(37). Therefore, we tested whether BBK32 might recognize
GAGs on the host cell surface, using 293 epithelial cells, a cell
line which we have previously shown to produce GAGs recog-
nized by B. burgdorferi (36).
Specific classes of GAGs on the surface of 293 cells were
enzymatically removed by digestion with lyases prior to binding
by B314/pBBK32 or, for comparison, strain B31. Removal of
heparin-, heparan sulfate-, or chondroitin sulfate-related GAGs
with heparinase, heparitinase, or chondroitinase ABC, respec-
tively, significantly reduced host cell binding by both of these
bacterial strains (Fig. 4A). Strain B31 appeared somewhat less
dependent on heparin- and heparan sulfate-related GAGs for
binding to 293 cells than did strain B314/pBBK32, consistent
with the fact that B31 produces DbpA and DbpB, which rec-
ognize chondroitin sulfates on this cell line (17). Combination
lyase digestion to remove diverse classes of GAGs from 293 cells
resulted in a further reduction of binding by B314/pBBK32
(Fig. 4A). The putative recognition of GAGs by BBK32 pre-
dicts that exogenous GAGs should inhibit attachment of B314/
pBBK32 to 293 cells. Strain B314/pBBK32, or for comparison
strain B31, was incubated with purified GAGs prior to binding
to 293 cells. Heparin, a heparan sulfate analog, and dermatan
sulfate both blocked binding, whereas chondroitin-6-sulfate
had no effect (Fig. 4B). Finally, to test whether GAGs are
sufficient to promote attachment of B. burgdorferi expressing
BBK32, B314/pBBK32 was tested for the ability to attach to
purified GAGs immobilized in microtiter wells. This strain,
like strain B31, attached to wells coated with dermatan sulfate
or heparin even more efficiently than to wells coated with
fibronectin (Fig. 4C). As predicted, neither strain bound to
wells coated with chondroitin-6-sulfate.
To determine whether attachment of strain B314/pBBK32
was due to a direct interaction between BBK32 and GAGs,
recombinant MBP-BBK32 was tested for the ability to bind to
purified heparin, or as a control, fibronectin, immobilized in
microtiter wells. As expected, MBP-BBK32 bound to fibronec-
tin, and with an efficiency 10-fold higher than MBP (Fig. 5). In
addition, while MBP-BBK32 did not bind to chondroitin-6-
sulfate, it recognized heparin as efficiently as it did fibronectin.
These results indicate that BBK32 is capable of promoting B.
burgdorferi attachment to mammalian cells by recognizing GAGs
or fibronectin.
Bacterial attachment to fibronectin mediated by BBK32 is
not inhibitable by heparin. The BBK32 fibronectin-binding do-
main has been localized by deletion analysis to residues 131 to
162 in the unordered N-terminal half of BBK32 (26, 40, 42).
If the same domain also promotes GAG binding, exogenous
FIG. 4. B. burgdorferi producing BBK32 binds to GAGs on the surface of epithelial cells. (A) Radiolabeled strains B31, B314/pJF21 (“B314/
vector”), and B314/pBBK32 were added to wells containing monolayers of 293 epithelial cells that had been mock treated or treated with
heparinase, heparitinase, or chondroitinase ABC. The percentage of cells stably bound was determined by scintillation counting. Hep., heparinase
digestion; Hpt., heparitinase digestion; Chon. ABC, chondroitinase ABC digestion. Asterisks indicate that binding of B314/pBBK32 to cells treated
with the denoted lyases or combination of lyases was significantly (P  0.05) less than binding to mock-treated cells. In addition, cell binding after
treatment with a combination of lyases was significantly (P  0.05) less than binding after any single lyase treatment. (B) Radiolabeled strains B31
and B314/pBBK32 were incubated with PBS alone or 2 mg/ml of the indicated GAG for 30 min prior to incubation with monolayers of 293
epithelial cells, and the percent of cells stably bound was determined. “Derm SO4,” dermatan sulfate; “Chon-6-SO4,” chondroitin-6-sulfate. Each
bar represents the mean of four independent determinations  the standard deviation (SD). Incubation of B314/pBBK32 with dermatan sulfate
or heparin significantly reduced (P  0.05; asterisks) spirochete attachment to epithelial cells compared to incubation with chondroitin-6-sulfate.
Binding of B314/pBBK32 to cells treated with multiple lyases significantly reduced (P  0.05) binding compared to spirochetes binding to cells
treated with the indicated single lyases. (C) Radiolabeled strains B31, B314/pJF21 (“vector”), and B314/pBBK32 were added to mock-coated wells
or wells coated with the indicated GAG or fibronectin, and the percentage of cells stably bound was determined. Each bar represents the mean
of four independent determinations  SD. Asterisks indicate that binding of B314/pBBK32 to wells coated with dermatan sulfate, heparin, or
fibronectin was significantly greater (P  0.05) than binding of B314/vector.
TABLE 1. Fibronectin is not detectable on the surface
of HEp-2 epithelial cellsa
Cells Relative fibronectinexpression
None ....................................................................................0.00  0.01
293 epithelial ......................................................................0.15  0.03*
EAhy-926 endothelial........................................................0.14  0.05*
C6 glial ................................................................................0.16  0.08*
HEp-2 epithelial.................................................................0.01  0.01
a Microtiter wells containing monolayers of the indicated cell lines were tested
for the presence of fibronectin by ELISA using a polyclonal antibody against
fibronectin. Stably bound antifibronectin antibody was quantitated with an anti-
rabbit antibody conjugated with horseradish peroxidase, and the absorbance at
650 nm was determined. Each point represents the mean of four independent
determinations  the standard deviation. Wells containing cell monolayers with
relative fibronectin expression significantly (P  0.05) greater than wells without
mammalian cells are indicated with an asterisk.
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GAGs might inhibit BBK32-mediated spirochetal attachment
to fibronectin. We found that a high (2-mg/ml) concentration
of heparin did not diminish attachment of B314/pBBK32 to
immobilized fibronectin (Fig. 6). In contrast, binding of this
strain to immobilized heparin was diminished fivefold by ex-
ogenous heparin, and this inhibition was specific to heparin
because chondroitin-6-sulfate had no effect. These results sug-
gest that recognition of fibronectin and GAG binding repre-
sent independent activities of BBK32.
DISCUSSION
The development of vectors capable of replication in B.
burgdorferi has facilitated new approaches in the study of vir-
ulence-associated phenotypes of B. burgdorferi (13, 47). We
previously utilized complementation of the high-passage non-
adherent B. burgdorferi strain B314 as a straightforward assay
for surface molecules that promote spirochetal attachment to
mammalian cells and uncovered previously unrecognized GAG-
binding activities of the decorin binding proteins DbpA and
DbpB (17). Here we utilized the ospC promoter, which is
active during in vitro culture, to ectopically express lipoprotein
BBK32 in strain B314 and found that BBK32 promoted bac-
terial attachment to purified fibronectin and to mammalian
cells in vitro, thus confirming that it indeed functions as a
fibronectin-binding adhesin. In addition, production of BBK32
by strain B314 revealed a second adhesive activity, one that
promotes binding to diverse mammalian cells through the rec-
ognition of dermatan sulfate and heparan sulfate.
It seems likely that the fibronectin- and GAG-binding activ-
ities of BBK32 are independent, because high concentrations
of heparin could not diminish binding of B314/pBBK32 to
immobilized fibronectin. These results confirm those of John-
son and coworkers, who showed, using far-Western assays, that
heparin did not inhibit binding of fibronectin to BBK32 (39).
In addition, the fibronectin-binding domain identified by these
investigators, amino acids 131 to 162 (40), contains highly
conserved acidic amino acids and seems unlikely to interact
with GAGs, which are also highly negatively charged.
B. burgdorferi strain B314 producing BBK32 bound to HEp-2
cells, which did not produce fibronectin detectable by enzyme-
linked immunosorbent assay (ELISA), suggesting that GAGs
are sufficient to promote BBK32-mediated bacterial adhesion
to mammalian cells. In addition, enzymatic removal of GAGs
from 293 epithelial cells resulted in an eightfold decrease in
binding by B314/pBBK32, suggesting that GAGs represent the
major 293 cell receptor for BBK32. In contrast, enzymatic
removal of GAGs expressed by Chinese hamster ovary (CHO)
cells did not diminish binding by B314/pBBK32, and this re-
combinant strain bound to CHO cells deficient for GAG syn-
thesis as efficiently as to wild-type CHO cells (J. R. Fischer,
unpublished observations). Hence, the relative contribution of
GAGs and fibronectin to cell attachment may vary with the
target cell.
B. burgdorferi strain N40, when grown in dialysis membrane
chambers in the rat peritoneum, a condition designed to mimic
conditions of growth during mammalian infection (1), pro-
duces a marked increase in binding to purified heparin and to
heparan sulfate produced by EAhy-926 endothelial cells (37).
Recombinant derivatives of the previously identified GAG bind-
ing ligands, Bgp, DbpA and DbpB, were incapable of efficiently
inhibiting GAG-mediated cell binding by host-adapted B. burg-
dorferi strain N40, suggesting that this strain produces other
GAG-binding surface molecules. BBK32 is not produced by
strain N40 during in vitro culture or in the unfed tick but is
induced upon tick feeding and mammalian infection (15). Al-
though the regulation of BBK32 in strain N40 appears to differ
from that in B31 (39) and although it is unclear whether
BBK32 of strain B31 is upregulated in the mammalian host (3),
FIG. 5. BBK32 binds to heparin. Recombinant MBP-BBK32 or MBP
proteins were added to fibronectin- or GAG-coated wells, and bound
protein was quantitated by measuring absorbance at 650 nm after ELISA
using MBP antiserum and an anti-rabbit horseradish peroxidase-conju-
gated secondary antibody. “Chon-6-SO4,” chondroitin-6-sulfate. Each bar
represents the mean of four independent determinations  the standard
deviation. Asterisks indicate that recombinant MBP-BBK32 bound
wells coated with fibronectin or heparin significantly better (P  0.05)
than MBP.
FIG. 6. Attachment of B. burgdorferi producing BBK32 to fibronec-
tin is not inhibited by exogenous heparin. Radiolabeled B314/pBBK32
was incubated with the indicated 2 mg/ml heparin prior to addition to
fibronectin- or heparin-coated wells, and the percentage of cells stably
bound was determined. Each bar represents the mean of four inde-
pendent determinations  the standard deviation. The asterisk indi-
cates that incubation of B314/pBBK32 with heparin resulted in signifi-
cantly less (P 0.05) spirochetal binding to wells coated with heparin than
incubation with chondroitin-6-sulfate.
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BBK32 expression in strain B31 cultured in vitro is neverthe-
less induced upon exposure to mammalian blood (51), consis-
tent with the hypothesis that BBK32 may promote cell adhe-
sion of B. burgdorferi during mammalian infection. Thus, the
present finding that BBK32 promotes spirochetal attachment
to GAGs suggests that this adhesin may contribute to the
observed induction of GAG-binding activity by strain N40. We
cannot easily test this hypothesis with strain B314/pBBK32
because it lacks lp25, which is required for growth in implanted
dialysis membrane chambers. However, our recent isolation of
a defined BBK32 mutant of strain B31 will permit a rigorous
test of the role of BBK32 in GAG binding by host-adapted
bacteria (Fischer, unpublished).
Previously observed B. burgdorferi strain differences in
GAG-binding specificity were hypothesized to result from the
expression of different sets of GAG-binding adhesins, each
with unique specificity (36). BBK32 now joins DbpA and DbpB
as B. burgdorferi proteins that have been documented to me-
diate spirochetal attachment to GAGs when expressed on the
bacterial surface (17). (Bgp is also a candidate GAG-binding
adhesin, but ectopic expression of bgp in strain B314 did not
result in a detectable increase in cell attachment (K. T. LeBlanc,
unpublished observation). As predicted, each of these three
adhesins demonstrates unique GAG-binding and cell-binding
specificities. We previously showed that DbpA mediates bac-
terial attachment to purified dermatan sulfate and 293 cells
(17). DbpB possesses these same activities but additionally
promotes binding to purified chondroitin-6-sufate and C6 glial
cells. Neither DbpA nor DbpB is capable of promoting spiro-
chetal attachment to EA-Hy926 endothelial cells. In contrast,
we showed here that BBK32 promotes bacterial binding to
purified heparin as well as to dermatan sulfate and promotes
binding to GAGs expressed by 293 epithelial cells, C6 glial
cells, and EA-Hy926 endothelial cells (Fig. 3) (Fischer, unpub-
lished). Differences in GAG binding mediated by the Vsp
proteins of B. turicatae are associated with differences in tissue
tropism (5, 33, 38, 54), suggesting that the GAG-binding ad-
hesins of B. burgdorferi similarly influence tissue colonization.
Consistent with this notion, infection of wild-type and decorin-
deficient mice suggested that decorin may promote the spread
of the pathogen and its survival in tissues that express relatively
high levels of decorin (4, 32). The present study indicates that
BBK32 and DbpA/DbpB not only recognize different protein-
associated receptors (fibronectin and decorin, respectively) but
also possess unique GAG-binding activities that provide po-
tentially nonredundant function during mammalian infection.
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